IFRX
IFRX clinical trials: InflaRx N.V.
Every trial on ClinicalTrials.gov where InflaRx N.V. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 12
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IFRX on the catalyst calendar · IFRX registry changes
- Primary completion Jan 22, 2026ActualPhase 2NCT06555328Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis SuppurativaInflaRx GmbH · Chronic Urticaria, IdiopathicTerminatedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 11, 2025ActualPhase 3NCT05964413Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumInflaRx GmbH · Pyoderma GangrenosumTerminatedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 4, 2024ActualPhase 2NCT04812535Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.InflaRx GmbH · SCC - Squamous Cell Carcinoma of SkinTerminatedIFRXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 3, 2022ActualPhase 2NCT03971643Exploratory Study of IFX-1 in Patients With Pyoderma GangrenosumInflaRx GmbH · Pyoderma GangrenosumCompletedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2021ActualPhase 2/Phase 3NCT04333420Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 PneumoniaInflaRx GmbH · Severe COVID-19 PneumoniaCompletedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2021ActualPhase 2NCT03895801Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.InflaRx GmbH · Granulomatosis With Polyangiitis (GPA)CompletedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 10, 2020ActualPhase 2NCT03712345Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPAInflaRx GmbH · Granulomatosis With Polyangiitis (GPA)TerminatedIFRXLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 27, 2019ActualPhase 2NCT03487276Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)InflaRx GmbH · Hidradenitis Suppurativa (HS)CompletedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2017ActualPhase 2NCT03001622Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis SuppurativaInflaRx GmbH · Hidradenitis SuppurativaCompletedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 2NCT02866825Studying Complement Inhibition in Complex Cardiac SurgeryInflaRx GmbH · Systemic Inflammatory Response SyndromeCompletedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 2NCT02246595Studying Complement Inhibition in Early, Newly Developing Septic Organ DysfunctionInflaRx GmbH · Severe SepsisCompletedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT01319903Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29InflaRx GmbH · Drug SafetyCompletedIFRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 2NCT06703073JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS)RecruitingEDSACollaboratorIFRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 2NCT06701682JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: VilobelimabPPD Development, LP · Acute Respiratory Distress Syndrome (ARDS)RecruitingEDSACollaboratorIFRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 2NCT06701669JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: ParidiprubartPPD Development, LP · Acute Respiratory Distress Syndrome (ARDS)RecruitingEDSACollaboratorIFRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 2NCT06701656JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: BevacizumabPPD Development, LP · Acute Respiratory Distress Syndrome (ARDS)RecruitingEDSACollaboratorIFRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner